This is a working overview of blood-brain barrier, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-03 and is reviewed periodically as new material appears.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
SUMOylation Also sumoylation. A type of post-translational modification in which a SUMO protein is conjugated to a polar residue of another protein (usually a lysine) via a covalent isopeptide bond. This effectively tags the second protein, making it distinguishable to other biomolecules and in many cases allowing it to participate in specific reactions or to interact with specific protein complexes. SUMOlyation is closely related to ubiquitination, relying on the same E1/E2/E3 enzymes to transfer SUMO to specific recognition motifs in the target protein, though detaching SUMO depends on SUMO-specific proteases. It plays important roles in numerous cellular processes, including protein localization, transcriptional regulation, stress-response pathways, and cell cycle checkpoints, among others. SUMOlyation is also used in the laboratory as a molecular label and to help solubilize proteins which are difficult to purify.
=== Density === The highest density of CNTs was achieved in 2013, grown on a conductive titanium-coated copper surface that was coated with co-catalysts cobalt and molybdenum at lower than typical temperatures of 450 °C. The tubes averaged a height of 380 nm and a mass density of 1.6 g cm−3. The material showed ohmic conductivity (lowest resistance ~22 kΩ).
Three people were killed in a Russian missile attack on Dnipro. In Russia, the governor of Tambov Oblast claimed that an oil depot was set on fire by a drone strike. Seven Ukrainian drones struck the Novolipetsk Metallurgical Plant in Lipetsk, damaging its oxygen station and oxygen separation unit without causing casualties. The National Guard of Ukraine claimed to have shot down a Russian Su-25 fighter jet over Donetsk Oblast using an Igla missile. Ukrainian media reported an ATACMS missile destroyed either a S-400 or S-500 missile system, using cluster bombs, at an unknown location in Crimea. Zelenskyy announced the release of ten Ukrainian civilians held by Russia, some of whom had been arrested in Belarus and Russian-occupied areas in Ukraine since 2017, following an agreement mediated by the Vatican. A Russian milblogger released images of Russian soldiers using North Korean shells for M-46 howitzer, written on some of the shells was "for Sevastopol".
Sources: en.wikipedia.org
==== Adherence ==== Poor compliance with medications and follow-up visits are a major reason for treatment failure and disease progression in glaucoma patients. Poor adherence could lead to increased complication rates, thus increasing the need for non-pharmacological interventions, including surgery. Patient education and communication must be ongoing to sustain successful treatment plans for this lifelong disease with no early symptoms.
== Nuclear fuel cycle == The nuclear fission properties of berkelium are different from those of the neighboring actinides curium and californium, and they suggest berkelium to perform poorly as a fuel in a nuclear reactor. Specifically, berkelium-249 has a moderately large neutron capture cross section of 710 barns for thermal neutrons, 1200 barns resonance integral, but very low fission cross section for thermal neutrons. In a thermal reactor, much of it will therefore be converted to berkelium-250 which quickly decays to californium-250. In principle, berkelium-249 can sustain a nuclear chain reaction in a fast breeder reactor. Its critical mass is relatively high at 192 kg, which can be reduced with a water or steel reflector but would still exceed the world production of this isotope. Berkelium-247 can maintain a chain reaction both in a thermal-neutron and in a fast-neutron reactor, however, its production is rather complex and thus the availability is much lower than its critical mass, which is about 75.7 kg for a bare sphere, 41.2 kg with a water reflector and 35.2 kg with a steel reflector (30 cm thickness).
=== Microspheres === Microspheres are hollow, micron-sized carriers often formed via self-assembly of polymeric compounds which are most often used to encapsulate the active drug for delivery. Drug release is often achieved by diffusion through pores in the microsphere structure or by degradation of the microsphere shell. Some of the research currently being done uses advanced assembly techniques, such as precision particle fabrication (PPF), to create microspheres capable of sustained control over drug release.
== General mammalian research == Migliaro Petroni et al. (2026) describe tracks of a small-bodied, fast-moving mammal from the Upper Cretaceous (Maastrichtian) strata of the Yacoraite Formation (Argentina), assigned to the ichnotaxon Brasilichnium cf. saltatorium and extending known stratigraphic distribution of the ichnogenus Brasilichnium. A new, diverse assemblage of teeth of Paleocene (Torrejonian) mammals is reported from the Tullock Member of the Fort Union Formation (Montana, United States) by Hovatter & Wilson Mantilla (2026). Evidence indicating that carbon isotope excursions and probable warming events during the Danian were associated with strong pulses of turnover of mammalian assemblages is reported from the study of the fossil record from the San Juan Basin (New Mexico, United States) and other basins in the Rocky Mountain Region is presented by Secord et al. (2026). Evidence from the study of teeth of Paleocene placentals from the Nanxiong, Qianshan and Chijiang basins (China), indicating that the studied mammals achieved high dental topographic variability during the first 10 million years of the Cenozoic and that the variability of their dental traits paralleled global and regional environmental changes, is presented by Tseng, Li & Ting (2026), who argue that living placental lineages might originate from phenotypically variable and functionally flexible ancestors such as the mammals from the studied assemblages from paleotropical Asia.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.